1-(4-Amino-5-chloro-2-methoxyphenyl)-3-(1-((4-methoxyphenyl)sulfonyl)piperidin-4-yl)propan-1-one

ID: ALA4743835

Chembl Id: CHEMBL4743835

PubChem CID: 162645279

Max Phase: Preclinical

Molecular Formula: C22H27ClN2O5S

Molecular Weight: 466.99

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1ccc(S(=O)(=O)N2CCC(CCC(=O)c3cc(Cl)c(N)cc3OC)CC2)cc1

Standard InChI:  InChI=1S/C22H27ClN2O5S/c1-29-16-4-6-17(7-5-16)31(27,28)25-11-9-15(10-12-25)3-8-21(26)18-13-19(23)20(24)14-22(18)30-2/h4-7,13-15H,3,8-12,24H2,1-2H3

Standard InChI Key:  BLTGJELNKQOBPV-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4743835

    ---

Associated Targets(Human)

HTR6 Tchem Serotonin 6 (5-HT6) receptor (9749 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

HTR4 Serotonin 4 (5-HT4) receptor (2870 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 466.99Molecular Weight (Monoisotopic): 466.1329AlogP: 4.00#Rotatable Bonds: 8
Polar Surface Area: 98.93Molecular Species: NEUTRALHBA: 6HBD: 1
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 1.28CX LogP: 2.95CX LogD: 2.95
Aromatic Rings: 2Heavy Atoms: 31QED Weighted: 0.47Np Likeness Score: -1.13

References

1. Yahiaoui S,Hamidouche K,Ballandonne C,Davis A,de Oliveira Santos JS,Freret T,Boulouard M,Rochais C,Dallemagne P.  (2016)  Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease.,  121  [PMID:27266998] [10.1016/j.ejmech.2016.05.048]

Source